Sumitomo Mitsui Trust Group Inc. Cuts Holdings in Baxter International Inc. $BAX

Posted by Jessica Moore on Jul 17th, 2026

Sumitomo Mitsui Trust Group Inc. lowered its stake in Baxter International Inc. (NYSE:BAX – Free Report) by 97.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,317 shares of the medical instruments supplier’s stock after selling 1,250,135 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Baxter International were worth $493,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in BAX. Geode Capital Management LLC increased its stake in shares of Baxter International by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 13,510,205 shares of the medical instruments supplier’s stock worth $257,174,000 after buying an additional 972,891 shares during the period. Greenhaven Associates Inc. lifted its stake in Baxter International by 70.0% in the fourth quarter. Greenhaven Associates Inc. now owns 10,693,223 shares of the medical instruments supplier’s stock worth $204,347,000 after acquiring an additional 4,404,874 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Baxter International by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock worth $231,304,000 after acquiring an additional 97,687 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Baxter International by 35.6% during the 4th quarter. Russell Investments Group Ltd. now owns 3,410,689 shares of the medical instruments supplier’s stock worth $65,216,000 after acquiring an additional 894,761 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC increased its position in shares of Baxter International by 12.0% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 3,328,202 shares of the medical instruments supplier’s stock valued at $63,602,000 after purchasing an additional 356,612 shares during the last quarter. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Trading Up 5.5%

Shares of Baxter International stock opened at $23.36 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.23 and a debt-to-equity ratio of 1.43. The company has a fifty day simple moving average of $20.16 and a 200-day simple moving average of $19.33. The stock has a market cap of $12.06 billion, a price-to-earnings ratio of -10.97, a PEG ratio of 3.58 and a beta of 0.62. Baxter International Inc. has a 12-month low of $15.73 and a 12-month high of $29.35.

Baxter International (NYSE:BAX – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.36 EPS for the quarter, topping the consensus estimate of $0.31 by $0.05. Baxter International had a negative net margin of 9.70% and a positive return on equity of 16.15%. The firm had revenue of $2.70 billion for the quarter, compared to analyst estimates of $2.62 billion. During the same period last year, the business earned $0.62 EPS. Baxter International’s revenue for the quarter was up 2.9% compared to the same quarter last year. On average, equities analysts forecast that Baxter International Inc. will post 1.91 EPS for the current fiscal year.

Baxter International Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 1st. Stockholders of record on Friday, May 29th were issued a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend was Friday, May 29th. Baxter International’s payout ratio is presently -1.88%.

Baxter International News Summary

Here are the key news stories impacting Baxter International this week:

Positive Sentiment: Goldman Sachs raised its price target on Baxter International to $21 from $19, signaling somewhat improved valuation expectations even though the firm kept a neutral rating. Baxter International (NYSE:BAX) Given New $21.00 Price Target at The Goldman Sachs Group
Neutral Sentiment: News also highlighted that Baxter’s chart has formed a golden cross, a technical signal some traders view as constructive for near-term momentum. AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap
Negative Sentiment: Zacks Research cut its earnings estimates for Baxter across multiple periods, including Q2 2026, FY2026, FY2027 and FY2028, while also downgrading the stock to Strong Sell, which suggests concerns about profit growth. Zacks.com downgrade
Neutral Sentiment: Baxter also updated its segment reporting structure and metrics, but the filing did not appear to include a major operating surprise. Baxter International Updates Segment Reporting Structure and Metrics

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BAX. Barclays raised their price objective on shares of Baxter International from $25.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, May 1st. The Goldman Sachs Group increased their target price on Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday. Weiss Ratings raised Baxter International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. TD Cowen lowered their price objective on Baxter International from $22.00 to $20.00 in a research report on Friday, May 1st. Finally, Stifel Nicolaus dropped their price objective on Baxter International from $20.00 to $19.00 in a report on Friday, May 1st. Two investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $19.91.

Get Our Latest Analysis on BAX

About Baxter International

(Free Report)

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.